COVID-19 vaccines: current and future challenges
- PMID: 39568586
- PMCID: PMC11576167
- DOI: 10.3389/fphar.2024.1434181
COVID-19 vaccines: current and future challenges
Abstract
As of December 2020, around 200 vaccine candidates for Coronavirus Disease 2019 (COVID-19) are being developed. COVID-19 vaccines have been created on a number of platforms and are still being developed. Nucleic acid (DNA, RNA) vaccines, viral vector vaccines, inactivated vaccines, protein subunit vaccines, and live attenuated vaccines are among the COVID-19 vaccine modalities. At this time, at least 52 candidate vaccines are being studied. Spike protein is the primary protein that COVID-19 vaccines are targeting. Therefore, it is critical to determine whether immunizations provide complete or fractional protection, whether this varies with age, whether vaccinated people are protected from reoccurring diseases, and whether they need booster shots if they've already been inoculated. Despite the enormous achievement of bringing several vaccine candidates to market in less than a year, acquiring herd immunity at the national level and much more so at the global level remains a major challenge. Therefore, we gathered information on the mechanism of action of presently available COVID-19 vaccines in this review and essential data on the vaccines' advantages and downsides and their future possibilities.
Keywords: COVID-19; coronavirus disease (COVID)-19; immunity; vaccination; vaccine.
Copyright © 2024 Mohammadi, Ghasemi, Manouchehrian, Zafarmand, Akbari and Boroumand.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- AbdulRahman A. S., Faten F. M., Asmaa A. M. (2024). “SARS-CoV-2 secondary spillover: from doubt to evidence,” in Current topics in zoonoses. Editor Alfonso J. R.-M. (Rijeka: IntechOpen; ). Available at: https://www.intechopen.com/chapters/89040
-
- Angyal A., Longet S., Moore S. C., Payne R. P., Harding A., Tipton T., et al. (2022). T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe 3 (1), e21–e31. 10.1016/S2666-5247(21)00275-5 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials